• 1. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 2. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 3. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 4. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 5. Alt-proteins: A promising future

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzamides
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzamides

Recent Advances in the Study of 2-(Piperazine-1-carbonyl)-benzoic Acid (CAS: 37618-28-3)

2-(Piperazine-1-carbonyl)-benzoic Acid (CAS: 37618-28-3) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This molecule, characterized by its piperazine and benzoic acid moieties, has been the subject of numerous studies due to its potential applications in drug development, particularly as a building block for more complex pharmacologically active compounds. Recent research has focused on its synthesis, structural modifications, and biological activities, aiming to explore its full therapeutic potential.

One of the key areas of investigation has been the optimization of synthetic routes for 2-(Piperazine-1-carbonyl)-benzoic Acid. A study published in the Journal of Medicinal Chemistry (2023) demonstrated an efficient and scalable synthesis method, achieving high yields and purity. The researchers employed a combination of solid-phase synthesis and microwave-assisted techniques, which significantly reduced reaction times and improved overall efficiency. This advancement is particularly relevant for industrial-scale production, where cost-effectiveness and reproducibility are critical factors.

In addition to synthetic improvements, recent studies have explored the biological activities of 2-(Piperazine-1-carbonyl)-benzoic Acid and its derivatives. A 2023 paper in Bioorganic & Medicinal Chemistry Letters reported that this compound exhibits moderate inhibitory activity against certain kinases involved in inflammatory pathways. The study utilized molecular docking simulations and in vitro assays to identify potential binding modes and mechanisms of action. These findings suggest that 2-(Piperazine-1-carbonyl)-benzoic Acid could serve as a lead compound for the development of novel anti-inflammatory agents.

Another significant development is the application of 2-(Piperazine-1-carbonyl)-benzoic Acid in the design of hybrid molecules. Researchers have conjugated this compound with other pharmacophores to create multi-target ligands with enhanced therapeutic profiles. For instance, a recent study in European Journal of Medicinal Chemistry (2024) described the synthesis of a series of hybrid molecules combining 2-(Piperazine-1-carbonyl)-benzoic Acid with known anticancer scaffolds. Preliminary results indicated promising cytotoxicity against several cancer cell lines, with minimal effects on normal cells, highlighting its potential in oncology drug discovery.

Despite these advancements, challenges remain in fully elucidating the pharmacokinetic and pharmacodynamic properties of 2-(Piperazine-1-carbonyl)-benzoic Acid. A 2023 review in Expert Opinion on Drug Metabolism & Toxicology pointed out the need for more comprehensive in vivo studies to assess absorption, distribution, metabolism, and excretion (ADME) profiles. Such studies are essential for translating preclinical findings into clinical applications and ensuring the safety and efficacy of future drug candidates derived from this compound.

In conclusion, 2-(Piperazine-1-carbonyl)-benzoic Acid (CAS: 37618-28-3) continues to be a valuable molecule in chemical biology and pharmaceutical research. Recent studies have advanced our understanding of its synthesis, biological activities, and potential therapeutic applications. However, further research is needed to address existing gaps, particularly in pharmacokinetics and in vivo efficacy. The ongoing exploration of this compound and its derivatives holds promise for the development of new drugs targeting various diseases, including inflammation and cancer.

• 53663-18-6(2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]benzoic acid)
• 691394-20-4(4-(piperazine-1-carbonyl)-benzoic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)